Blog Read the latest perspectives from our team of subject matter experts and others Redefining Medical Affairs Strategy with DataAs the role of Medical Affairs continues to evolve, data plays an increasingly critical role in shaping key opinion leader (KOL) engagement strategies, identifying care gaps, and ensuring equitable… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact HCP Volunteers KOL Engagement Patient Representation Provider Data Research Post Industries:Commercialization Global Impact Health Plans & Digital Health Pharmaceutical & Biotechnology Provider Data Research Drug DevelopmentPatient RepresentationEthics and Equity in Clinical Trials & FDA Diversity Guidance PrepClinical trials serve as the bedrock for advancements in medicine, guiding the development of new treatments and therapies. However, a critical issue plaguing these trials is the lack of… Continue reading → Read the articleno Artificial IntelligenceKOL EngagementProvider DataA Holistic Approach to Measuring ImpactMedical Affairs plays an essential role in evidence-based medicine, disease education, and driving better outcomes. Their knowledge is crucial as medications become more specialized and complex. They enable healthcare… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchTrials, Data, Diversity – H1’s Top 5 Diagnoses (Predictions) for Biotech and Pharma in 2024How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentSix Possible Implications of Biden’s Executive Order on AI for Life SciencesThe life sciences sector stands on the brink of a new era marked by the confluence of artificial intelligence (AI) and biomedicine. With President Biden’s recent Executive Order on AI,… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationWhy Clinical Trial Success Criteria Matters: 5 Essential QuestionsAs the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. With the rise of… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationOptimizing Clinical Data Registries: Opportunities for Diversity and FeasibilityIn an October 2023 report, BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical… Continue reading → Read the articleno‹12345›»
